Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

August 5, 2019

Study Completion Date

August 5, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Omeprazole

Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.

DRUG

Placebo oral tablet

Placebo will be administered orally once daily for 5 days in one of the two treatment periods.

DRUG

Gliclazide

Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.

Trial Locations (1)

71000

General Hospital Prim. Dr. Abdulah Nakas, Sarajevo

All Listed Sponsors
collaborator

General Hospital Prim. Dr. Abdulah Nakas

OTHER

collaborator

University of Dundee

OTHER

collaborator

Wellcome Trust

OTHER

lead

University of Sarajevo

OTHER

NCT04198948 - Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers | Biotech Hunter | Biotech Hunter